Close
Nordic 9Nordic 9

Recipharm Venture Fund (investor - Venture Capital)

Sweden recipharm.com
See something wrong or missing? Let us know
Offices:Stockholm

Recipharm Venture Fund is part of Recipharm AB, a publicly listed Swedish company, active as a pharmaceutical contract development and manufacturing organization.

Average round investment:26.53M USD
Average number per year:1.0
Distribution: 2023 (1)2020 (1)2019 (1)
Portfolio companies: Switzerland NewBiologixSweden Cinclus PharmaSweden Pharmanest
Mostly invests in: Sweden Sweden (2) Biotech (2)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Recipharm Venture Fund

Name Criteria
United States +ND Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Robert Andreen
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Michano
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States 5AM Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland LimmaTech Biologics AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Fresenius Medical Care Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland GF Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States 10X Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Roche Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Top